Phospho-CCDC88A (S1417) Antibody

What is the significance of CCDC88A phosphorylation at Serine 1417?

CCDC88A (also known as Girdin or GIV) phosphorylation at Serine 1417 represents a critical post-translational modification that regulates multiple cellular functions. This phosphorylation site is particularly important because it modulates CCDC88A's function as a key regulator of the AKT-mTOR signaling pathway. When phosphorylated at S1417, CCDC88A enhances PI3K-dependent activation of AKT by growth factor receptor tyrosine kinases and G protein-coupled receptors . This phosphorylation event is implicated in controlling the tempo of newborn neuron integration during adult neurogenesis, including correct neuron positioning, dendritic development, and synapse formation . Additionally, phosphorylation at S1417 influences CCDC88A's role in cell migration processes, which has significant implications for cancer metastasis research.

How specific is the Phospho-CCDC88A (S1417) antibody?

The Phospho-CCDC88A (S1417) antibody demonstrates high specificity for the phosphorylated form of CCDC88A. According to validation studies, this antibody detects endogenous levels of CCDC88A only when phosphorylated at serine 1417 . Specificity has been confirmed through multiple methods:

• Immunohistochemical analysis with and without blocking peptide controls shows clear differential staining

• ELISA tests demonstrate significantly higher binding to phosphopeptide compared to non-phosphopeptide

• Cross-reactivity tests confirm specificity across human and mouse samples

For rigorous experimental design, researchers should include appropriate controls, particularly when investigating tissues or cell lines with varying expression levels of CCDC88A.

What is the recommended protocol for immunohistochemistry using Phospho-CCDC88A (S1417) antibody?

For optimal immunohistochemical detection of phosphorylated CCDC88A (S1417), follow this validated protocol:

Sample Preparation:

• Fix tissue in 10% neutral buffered formalin and embed in paraffin

• Section tissues at 4-6 μm thickness

• Mount sections on positively charged slides

Staining Protocol:

• Deparaffinize sections in xylene and rehydrate through graded alcohols

• Perform heat-induced epitope retrieval using citrate buffer (pH 6.0)

• Block endogenous peroxidase with 3% H₂O₂ in methanol for 15 minutes

• Apply protein block (5% normal serum) for 1 hour at room temperature

• Incubate with primary antibody (diluted 1:50-1:300 in blocking solution) overnight at 4°C

• Wash 3 times with PBS-T (PBS + 0.1% Tween-20)

• Apply appropriate secondary antibody for 1 hour at room temperature

• Develop signal using DAB substrate

• Counterstain with hematoxylin, dehydrate, and mount

For validation and specificity control, include a parallel section incubated with the antibody pre-absorbed with the phospho-peptide immunogen . This approach has been demonstrated to significantly reduce or eliminate specific staining, confirming antibody specificity.

How should researchers optimize antibody dilution for their specific experimental system?

Determining the optimal antibody dilution requires systematic titration based on your specific experimental conditions. Follow this methodological approach:

• Initial Titration Range Selection:

  • Begin with the manufacturer's recommended dilution range (1:50-1:300 for IHC)

  • Prepare multiple dilutions spanning this range (e.g., 1:50, 1:100, 1:200, 1:300)

• Pilot Experiment Design:

  • Use known positive control samples (human breast carcinoma tissue has been validated)

  • Include negative controls:

    • Antibody diluent only (no primary antibody)

    • Antibody pre-absorbed with blocking peptide

    • Sample known to lack CCDC88A expression

• Signal-to-Noise Evaluation:

  • Assess specific staining intensity relative to background

  • Document results with standardized image acquisition settings

  • Create a quantitative scoring system (e.g., 0-4+ scale)

• Refinement:

  • If optimal dilution falls between tested points, perform a second round of testing with narrower dilution increments

  • Validate final dilution across multiple samples/experimental conditions

This methodical approach ensures reproducible results while minimizing non-specific background staining and optimizing signal detection.

What controls should be included when using Phospho-CCDC88A (S1417) antibody?

Rigorous experimental design requires appropriate controls to validate antibody specificity and experimental results:

Essential Controls:

• Positive Control:

  • Known phospho-CCDC88A (S1417) expressing tissue/cells

  • Human breast carcinoma tissue has been validated in multiple studies

• Negative Controls:

  • Antibody diluent without primary antibody (tests secondary antibody specificity)

  • Antibody pre-incubated with phospho-peptide blocking peptide (confirms epitope specificity)

  • Antibody pre-incubated with non-phosphorylated peptide (confirms phospho-specificity)

• Biological Controls:

  • Samples treated with phosphatase inhibitors vs. phosphatase treatment

  • Samples with manipulated signaling pathways known to affect S1417 phosphorylation

  • Time course following stimulation with growth factors that activate AKT signaling

• Technical Controls:

  • Antibody from different lots to ensure consistency

  • Range of antibody concentrations to establish optimal signal-to-noise ratio

  • Multiple detection methods when possible (e.g., IHC and Western blot)

Systematic implementation of these controls ensures confidence in experimental results and facilitates troubleshooting if unexpected outcomes occur.

How can Phospho-CCDC88A (S1417) antibody be used to investigate AKT-mTOR signaling pathway dynamics?

Phospho-CCDC88A (S1417) antibody offers a powerful tool for dissecting AKT-mTOR signaling cascades, particularly in contexts like neurogenesis and cancer progression. A comprehensive experimental approach includes:

• Temporal Signaling Dynamics Analysis:

  • Create a time-course experiment following growth factor stimulation

  • Co-stain for phospho-CCDC88A (S1417) alongside phospho-AKT and downstream effectors

  • Quantify relative phosphorylation kinetics to determine signaling sequence

• Pharmacological Intervention Strategy:

  • Employ specific inhibitors targeting:

    • PI3K (e.g., LY294002, Wortmannin)

    • AKT (e.g., MK-2206)

    • mTOR (e.g., Rapamycin, Torin)

  • Assess phospho-CCDC88A (S1417) levels via immunofluorescence or ELISA

  • Create dose-response curves to establish pathway dependencies

• Genetic Manipulation Approach:

  • Generate CCDC88A mutants (S1417A non-phosphorylatable, S1417D phosphomimetic)

  • Assess downstream AKT substrate phosphorylation patterns

  • Perform rescue experiments in CCDC88A knockdown backgrounds

• Subcellular Localization Studies:

  • Use phospho-CCDC88A (S1417) antibody for high-resolution immunofluorescence

  • Determine if phosphorylation alters protein localization

  • Co-localize with AKT pathway components using confocal microscopy

These methodologies can reveal how CCDC88A phosphorylation at S1417 serves as a key regulatory node within the broader AKT-mTOR signaling network, potentially identifying novel therapeutic targets for conditions with dysregulated signaling.

What approaches can be used to validate phospho-specificity in cell-based systems?

Validating phospho-specificity in cellular contexts requires multiple complementary approaches:

• Phosphatase Treatment Validation:

  • Split cell lysates into treated/untreated fractions

  • Incubate one fraction with lambda phosphatase

  • Compare phospho-CCDC88A (S1417) signal by immunoblotting

  • Expected outcome: Signal loss in phosphatase-treated samples

• Kinase Modulation Strategy:

  • Treat cells with AKT pathway activators (insulin, EGF, serum)

  • In parallel, pre-treat cells with PI3K/AKT inhibitors

  • Assess phospho-CCDC88A (S1417) levels via immunoblotting or immunofluorescence

  • Quantify dose-dependent phosphorylation changes

• Genetic Validation Approach:

  • Generate CCDC88A S1417A mutant cell lines via CRISPR/Cas9

  • Stimulate cells with AKT pathway activators

  • Probe with phospho-CCDC88A (S1417) antibody

  • Expected outcome: No signal in S1417A mutant regardless of stimulation

• Mass Spectrometry Correlation:

  • Immunoprecipitate CCDC88A following pathway stimulation

  • Perform phospho-mapping mass spectrometry

  • Correlate MS detection of S1417 phosphorylation with antibody signal

  • Establish quantitative relationship between methods

This multi-faceted approach ensures reliable detection of the phospho-epitope and provides critical validation of antibody specificity in cellular contexts, which is particularly important when investigating subtle changes in signaling dynamics.

How can researchers investigate the role of CCDC88A phosphorylation in cancer metastasis?

Investigating CCDC88A phosphorylation in cancer metastasis requires an integrated experimental approach:

• Patient Sample Analysis:

  • Create tissue microarrays from primary tumors and metastatic lesions

  • Perform IHC with phospho-CCDC88A (S1417) antibody (1:100 dilution)

  • Quantify staining intensity using digital pathology tools

  • Correlate phosphorylation levels with clinical outcomes and metastatic status

• In Vitro Metastasis Models:

  • Compare phospho-CCDC88A (S1417) levels between:

    • Paired low/high metastatic cancer cell lines

    • Patient-derived xenograft models with varying metastatic potential

  • Functional assays examining:

    • Cell migration (wound healing, transwell assays)

    • Invasion (Matrigel invasion assays)

    • Anoikis resistance (survival in suspension culture)

• Mechanistic Studies:

  • Generate stable cell lines expressing:

    • CCDC88A wild-type

    • S1417A (non-phosphorylatable)

    • S1417D (phosphomimetic)

  • Assess metastasis-associated phenotypes (invasion, migration)

  • Evaluate downstream effects on:

    • Cytoskeletal reorganization

    • Focal adhesion dynamics

    • AKT pathway activation

    • EMT marker expression

• In Vivo Metastasis Models:

  • Tail vein injection of cells with varying CCDC88A phosphorylation status

  • Orthotopic implantation with spontaneous metastasis monitoring

  • Bioluminescence imaging for longitudinal tracking

  • Terminal analysis of metastatic burden correlated with phospho-CCDC88A status

This systematic approach provides a comprehensive understanding of how CCDC88A phosphorylation at S1417 contributes to metastatic progression, potentially identifying novel therapeutic opportunities for metastasis prevention or treatment.

What are the common issues when using Phospho-CCDC88A (S1417) antibody in IHC, and how can they be resolved?

When working with Phospho-CCDC88A (S1417) antibody in immunohistochemistry applications, researchers may encounter several technical challenges:

Methodological approaches to improve phospho-specific IHC include immediate fixation of tissues, inclusion of phosphatase inhibitors in buffers, and optimization of antigen retrieval methods specific to phospho-epitopes.

How can researchers ensure phosphorylation status is maintained during sample preparation?

Preserving phosphorylation status is critical for accurate detection with phospho-specific antibodies. Follow these methodological guidelines:

• Tissue Collection Protocol:

  • Minimize ischemia time (ideally <20 minutes)

  • Place samples immediately in fixative containing phosphatase inhibitors

  • Consider collecting matched snap-frozen samples for verification studies

  • Document cold ischemia time for each specimen

• Fixation Optimization:

  • Use freshly prepared 10% neutral buffered formalin

  • Supplement fixative with phosphatase inhibitors:

    • Sodium fluoride (1 mM)

    • Sodium orthovanadate (1 mM)

    • β-glycerophosphate (1 mM)

  • Standard fixation time: 12-24 hours for small biopsies

• Cell Sample Processing:

  • For cultured cells, add phosphatase inhibitors to media 15 minutes before harvesting

  • Perform rapid lysis in buffer containing:

    • PMSF (1 mM)

    • Protease inhibitor cocktail (1X)

    • Phosphatase inhibitor cocktail (1X)

  • Maintain samples on ice throughout processing

• Storage Considerations:

  • Store antibody at -20°C in aliquots to avoid freeze-thaw cycles

  • For long-term storage of samples, use -80°C

  • Include glycerol (50%) in storage buffers when appropriate

Implementing these methodological approaches ensures maximal preservation of phosphorylation status and increases the likelihood of successful phospho-epitope detection.

What strategies can be employed to distinguish between specific and non-specific signals?

Distinguishing specific from non-specific signals requires rigorous controls and analytical approaches:

• Blocking Peptide Competition Assay:

  • Prepare three parallel samples:

    • Antibody only

    • Antibody pre-incubated with phospho-peptide

    • Antibody pre-incubated with non-phospho-peptide

  • Specific signal should be eliminated by phospho-peptide but not by non-phospho-peptide

  • Document results with standardized imaging parameters

• Signal Validation Through Multiple Detection Methods:

  • Compare results across techniques:

    • IHC/IF with phospho-CCDC88A (S1417) antibody

    • Western blot analysis

    • Phospho-ELISA quantification

  • Consistent results across methods strongly support specificity

• Genetic Knockdown/Knockout Validation:

  • Generate CCDC88A knockdown/knockout models

  • Perform staining with phospho-CCDC88A (S1417) antibody

  • True specific signal should be absent in genetic models lacking target protein

• Signal Modulation Through Biological Manipulation:

  • Treat samples with:

    • AKT pathway stimulators (should increase signal)

    • PI3K/AKT inhibitors (should decrease signal)

    • Lambda phosphatase (should eliminate signal)

  • Quantify signal changes under each condition

  • Specific phospho-signals will respond predictably to these manipulations

Implementing this multilayered approach provides robust validation of antibody specificity and confident discrimination between genuine phospho-CCDC88A (S1417) signal and experimental artifacts.

How should researchers quantify and interpret Phospho-CCDC88A (S1417) immunoreactivity in different experimental contexts?

Accurate quantification of Phospho-CCDC88A (S1417) immunoreactivity requires standardized methodologies tailored to specific experimental contexts:

• IHC/IF Tissue Section Analysis:

  • Scoring System Development:

    • H-score approach: Intensity (0-3) × percentage of positive cells (0-100%)

    • Allred score: Sum of proportion score (0-5) and intensity score (0-3)

    • Digital image analysis using calibrated software

  • Subcellular Localization Assessment:

    • Compartmentalized scoring (membrane vs. cytoplasmic vs. nuclear)

    • Co-localization analysis with organelle markers

    • Translocation quantification in response to stimuli

• Cell-Based Assays:

  • Single-Cell Analysis:

    • Mean fluorescence intensity measurements

    • Population distribution analysis (identify responding subpopulations)

    • Spatial analysis (leading edge vs. cell body in migration assays)

  • Time-Course Experiments:

    • Normalization to baseline (fold-change representation)

    • Area under curve calculations for temporal responses

    • Kinetic parameter extraction (time to peak, duration of response)

• Correlation Analysis:

  • Multi-Parameter Integration:

    • Correlation with other phosphorylation events in the pathway

    • Association with functional outputs (migration distance, proliferation rate)

    • Patient outcome correlations in clinical samples

• Statistical Approaches:

  • Appropriate Statistical Methods:

    • Non-parametric tests for scoring data (Mann-Whitney, Kruskal-Wallis)

    • ANOVA with post-hoc tests for multiple group comparisons

    • Survival analysis (Kaplan-Meier, Cox regression) for clinical correlations

When interpreting data, researchers should consider the biological context (basal vs. stimulated conditions), the relationship to other signaling events, and the functional consequences of CCDC88A phosphorylation in their specific experimental system.

What are the known relationships between CCDC88A phosphorylation and other signaling pathways?

CCDC88A phosphorylation at S1417 intersects with multiple signaling networks, creating a complex regulatory system:

Understanding these pathway intersections requires multiplexed analysis methods, where phospho-CCDC88A (S1417) detection is combined with readouts for other pathway components. This integrated approach reveals how CCDC88A phosphorylation serves as a signaling hub connecting diverse cellular processes.

How can researchers integrate phospho-CCDC88A data with broader -omics datasets?

Integrating phospho-CCDC88A (S1417) data with comprehensive -omics datasets requires systematic analytical approaches:

• Multi-Omics Integration Framework:

  • Correlative Analysis with Phosphoproteomics:

    • Identify co-regulated phosphorylation events using clustering algorithms

    • Construct kinase-substrate networks from global phosphoproteomic data

    • Position phospho-CCDC88A within the temporal phosphorylation cascade

  • Transcriptomics Connection:

    • Compare phospho-CCDC88A levels with transcriptional signatures

    • Identify gene expression programs regulated downstream of CCDC88A phosphorylation

    • Use gene set enrichment analysis (GSEA) to reveal functional pathways

  • Proteomics Intersection:

    • Analyze protein-protein interaction networks centered on phospho-CCDC88A

    • Identify phosphorylation-dependent interactome changes

    • Connect to protein abundance alterations downstream of signaling

• Computational Analysis Pipeline:

  • Network Analysis Approach:

    • Construct directed signaling networks using pathway databases

    • Map experimental phospho-CCDC88A data onto network models

    • Apply graph theory algorithms to identify regulatory modules

  • Machine Learning Implementation:

    • Develop predictive models for phospho-CCDC88A status based on multi-omic features

    • Use dimensionality reduction techniques to visualize complex datasets

    • Employ feature selection to identify key determinants of CCDC88A phosphorylation

• Functional Validation Strategy:

  • Hypothesis Generation:

    • Identify novel phospho-CCDC88A-dependent processes from integrated analysis

    • Prioritize targets based on network centrality and data correlation strength

  • Targeted Validation:

    • Design focused experiments testing computational predictions

    • Use CRISPR/Cas9 editing of predicted regulatory nodes

    • Validate signaling connections using phospho-specific antibodies

This multi-layered analytical framework places phospho-CCDC88A (S1417) within its broader biological context, revealing system-level functions beyond what can be observed through single-target studies alone.

What emerging technologies could enhance the detection and functional analysis of CCDC88A phosphorylation?

Several cutting-edge technologies offer promising approaches for advancing phospho-CCDC88A research:

• Advanced Imaging Technologies:

  • Proximity Ligation Assays (PLA):

    • Detect in situ interactions between phospho-CCDC88A and binding partners

    • Visualize complex formation in subcellular compartments

    • Quantify interaction dynamics following pathway stimulation

  • Live-Cell Phosphorylation Sensors:

    • Develop FRET-based biosensors for real-time CCDC88A phosphorylation

    • Monitor phosphorylation dynamics with subcellular resolution

    • Correlate with cell behavior in migration and adhesion assays

• Mass Spectrometry Innovations:

  • Targeted Phosphoproteomics:

    • Develop parallel reaction monitoring (PRM) assays for S1417 phosphopeptides

    • Achieve absolute quantification of phosphorylation stoichiometry

    • Multiplex with other signaling nodes for comprehensive pathway analysis

  • Spatial Mass Spectrometry:

    • Apply MALDI imaging mass spectrometry to tissue sections

    • Map phospho-CCDC88A distribution in tumor microenvironments

    • Correlate with cellular phenotypes and architectural features

• Single-Cell Technologies:

  • Single-Cell Phosphoproteomics:

    • Analyze phospho-CCDC88A heterogeneity within cell populations

    • Correlate with other signaling events at single-cell resolution

    • Identify rare cell populations with distinct phosphorylation patterns

  • Spatial Transcriptomics Integration:

    • Combine phospho-CCDC88A immunofluorescence with spatial transcriptomics

    • Map downstream transcriptional consequences in tissue context

    • Resolve spatial signaling domains within complex tissues

• Genome Editing Applications:

  • Knock-in Phosphosite Mutations:

    • Generate precise S1417A and S1417D knock-in models using CRISPR-Cas9

    • Create reporter cell lines with endogenous phospho-tagging

    • Develop animal models with phosphosite mutations for in vivo analysis

These emerging technologies will significantly enhance our ability to detect, quantify, and functionally characterize CCDC88A phosphorylation in diverse experimental contexts, from single molecules to whole organisms.

What are the most promising therapeutic implications of targeting CCDC88A phosphorylation?

CCDC88A phosphorylation at S1417 represents a potential therapeutic target with several promising applications:

• Cancer Metastasis Intervention:

  • Current Research Status:

    • Phospho-CCDC88A is implicated in cancer cell migration and invasion

    • Correlative studies show association with metastatic potential

    • Functions downstream of AKT in pathways promoting cancer progression

  • Therapeutic Approaches:

    • Develop peptide-based inhibitors blocking the S1417 phosphorylation site

    • Screen for small molecules disrupting phospho-CCDC88A interactions

    • Target phosphorylation-dependent protein-protein interactions

• Neurogenesis Modulation:

  • Therapeutic Potential:

    • Phospho-CCDC88A regulates newborn neuron integration

    • Modulating phosphorylation could enhance neurogenesis in neurodegenerative conditions

    • Potential applications in stroke recovery and neurodevelopmental disorders

  • Experimental Approach:

    • Test compounds that modulate AKT-dependent phosphorylation of CCDC88A

    • Evaluate effects on neural stem cell differentiation and integration

    • Develop targeted delivery systems for neural tissue

• Signaling Pathway Intersection:

  • Strategic Advantage:

    • Targeting phospho-CCDC88A affects multiple downstream pathways simultaneously

    • Potential to overcome resistance to single-pathway inhibitors

    • May provide synergistic effects with existing therapies

  • Combination Therapy Design:

    • Test phospho-CCDC88A inhibitors with AKT pathway drugs

    • Evaluate efficacy in resistant cancer models

    • Determine optimal sequencing of pathway-targeted agents

• Biomarker Development:

  • Clinical Application:

    • Use phospho-CCDC88A (S1417) antibodies for patient stratification

    • Develop companion diagnostics for AKT pathway inhibitors

    • Monitor treatment response based on phosphorylation status

  • Methodological Approach:

    • Standardize IHC protocols for clinical application

    • Develop quantitative assays for phospho-CCDC88A in liquid biopsies

    • Correlate levels with treatment outcomes in clinical trials

While significant preclinical validation remains necessary, the central role of CCDC88A phosphorylation in multiple disease-relevant processes makes it an attractive target for therapeutic development, particularly in precision medicine approaches for cancer and neurological disorders.

What are the key methodological considerations for studying CCDC88A phosphorylation in complex in vivo systems?

Investigating CCDC88A phosphorylation in complex in vivo systems presents unique challenges requiring specialized methodological approaches:

• Animal Model Development:

  • Genetically Engineered Models:

    • Generate knock-in mice with S1417A (non-phosphorylatable) mutations

    • Create conditional phospho-mutants for tissue-specific analysis

    • Develop reporter models expressing tagged CCDC88A for live imaging

  • Validation Considerations:

    • Confirm antibody specificity in mouse tissues using knockout controls

    • Establish baseline phosphorylation patterns across tissues and developmental stages

    • Determine optimal sample collection protocols to preserve phosphorylation status

• Tissue Analysis Techniques:

  • Phospho-Epitope Preservation:

    • Harvest tissues with minimal ischemia time (<2 minutes)

    • Immediately fix in phosphatase inhibitor-supplemented fixatives

    • Consider perfusion fixation for optimal phospho-epitope preservation

  • Advanced Imaging Methods:

    • Apply multiplexed immunofluorescence to detect pathway components

    • Use tissue clearing techniques for 3D phospho-mapping

    • Implement intravital microscopy for dynamic phosphorylation studies

• Context-Dependent Analysis:

  • Microenvironment Considerations:

    • Evaluate phospho-CCDC88A in relation to tissue architecture

    • Assess influence of stromal components on phosphorylation status

    • Consider oxygen gradients and metabolic influences on phosphorylation

  • Temporal Dynamics:

    • Design time-course studies capturing acute and chronic responses

    • Implement circadian controls for signaling studies

    • Develop strategies for longitudinal monitoring in the same animal

• Translation to Human Systems:

  • Patient Sample Analysis:

    • Standardize tissue collection protocols to preserve phosphorylation

    • Develop phospho-CCDC88A tissue microarrays with clinical annotation

    • Implement digital pathology for quantitative phospho-scoring

  • Comparison Methodologies:

    • Establish cross-species validation of phospho-antibodies

    • Identify conserved versus divergent signaling mechanisms

    • Correlate animal model findings with human patient data